Laws of Nature versus Man Made Creations: A Balancing Approach to Patent Eligibility in Assocation for Molecular Pathology v. Myriad Genetics, Inc. by Tariq, Salina
Science and Technology Law Review
Volume 17 | Number 1 Article 5
2014
Laws of Nature versus Man Made Creations: A
Balancing Approach to Patent Eligibility in
Assocation for Molecular Pathology v. Myriad
Genetics, Inc.
Salina Tariq
Follow this and additional works at: https://scholar.smu.edu/scitech
This Case Note is brought to you for free and open access by the Law Journals at SMU Scholar. It has been accepted for inclusion in Science and
Technology Law Review by an authorized administrator of SMU Scholar. For more information, please visit http://digitalrepository.smu.edu.
Recommended Citation
Salina Tariq, Laws of Nature versus Man Made Creations: A Balancing Approach to Patent Eligibility in Assocation for Molecular Pathology
v. Myriad Genetics, Inc., 17 SMU Sci. & Tech. L. Rev. 69 (2014)
https://scholar.smu.edu/scitech/vol17/iss1/5
LAWS OF NATURE VERSUS MAN MADE
CREATIONS: A BALANCING APPROACH TO





In the face of the growing concerns of patent eligibility in the fields of
science, the Supreme Court has continually attempted to make the law as
clear as possible. But given the evolutionary nature of scientific understand-
ing, the Court is not in the best position to, nor is capable of, introducing a
bright line rule that will encompass all future scientific discoveries. The na-
ture of scientific study is such that an "invention" in that field cannot possi-
bly be free of any reliance upon the laws of nature. Yet, the Supreme Court
in its decisions has consistently adhered to the laws of nature exception to
patent eligibility., While it is widely understood that "laws of nature" is es-
sentially a term of art, 2 with no specific definition, the Court has managed to
formulate a general understanding that the exception does not apply when the
product seeking patent protection has certain distinct characteristics from the
naturally-occurring product that it derives from.3 This definition has some-
what eased the difficulty faced by scientific innovators in negating the excep-
tion, given that it is inevitable that their products will include some natural
components. The determination of whether a product falls within this excep-
tion requires a case-by-case identification of the discovery or invention at
issue. The most important question in any patent eligibility suit then becomes
"What type of invention or discovery is it?"4
In the case of Association for Molecular Pathology v. Myriad Genetics,
Inc., the United States Supreme Court confronted the issue of patent eligibil-
ity of a scientific discovery pertaining to the isolation of human DNA se-
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1. Mayo Collaborative Servs. v. Prometheus Labs, Inc., 132 S. Ct. 1289, 1290
(2012).
2. Eileen M. Kane, Patent Ineligibility: Maintaining A Scientific Public Domain,
80 ST. JOHN'S L. REV. 519, 542 (2006).
3. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
4. See Kane, supra note 2, at 519.
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quences. 5 The Court once again struck down an argument for a broader
application of patent protection, holding that an isolation of DNA, albeit pos-
sible only after exhaustive experiments to find the DNA's precise location,
was not an "invention" for purposes of the patent law. 6 The Court thereby
solidified its existing interpretation that for a discovery to meet the "novel"
requirement of patent eligibility, it must involve the undertaking of an addi-
tional step that distinguishes the product discovered from the naturally-occur-
ring product that it is derived from.7 The Court's understanding was not only
consistent with its precedent, but also successful in balancing the twin goals
of the Patent Acts: encouraging new innovations by providing an economic
incentive and promoting such advancements by limiting the application of
patent protection. Finding broad patentable subject matter would restrict in-
novation to the potential accomplishments of a single mind. After all, how is
it possible to advance in the fields of science while simultaneously restricting
the use of scientific knowledge and tools? Doing both, as one critic illus-
trated, would be like allowing a single company to patent a generic invention
"car," causing all drivers to buy the car manufactured by that company, only
for it to turn out to be the unsafe Pinto.9
II. FACTUAL BACKGROUND
Certain medical patients, advocacy groups, and doctors brought an ac-
tion against Myriad Genetics, Inc. ("Myriad"), a research laboratory, seeking
a declaration that Myriad's patents for isolating DNA in genes and creating
composite DNA ("cDNA") were invalid.10
Myriad's chief scientist discovered the precise location and sequence of
two types of genes: BRCAI and BRCA2.11 The mutation of these genes has
been known to dramatically increase the risk of breast and ovarian cancer.12
This knowledge of the location enabled Myriad to isolate the genes and de-
velop certain medical tests for detecting mutations in a patient's BRACI and
BRAC2 genes.' 3 The tests were to be used to determine a patient's cancer
5. Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2109
(2013).
6. Id. at 2117.
7. See id. (quoting Chakrabarty, 477 U.S. at 309).
8. 35 U.S.C § 101.
9. Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercial Incen-
tives with Health Needs, 2 Hous. J. HEALTH L. & POL'Y 65, 90 (2002).
10. Myriad Genetics, 133 S. Ct. at 2114.
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risk.14 Following the discovery, Myriad obtained patents for isolating
BRCAI and BRCA2 genes and the synthetically created molecules of
cDNA.15 The patents were obtained so that Myriad would have the exclusive
right to isolate the DNA, which is necessary to obtain the genetic information
of the BRCA genes, and the exclusive right to synthetically create BRCA
cDNA. 16
Isolation of genes is necessary for genetic testing.17 Other laboratories,
including the University of Pennsylvania's Genetic Diagnostic Laboratories
("GDL"), offered BRCA testing once knowledge of such isolated sequences
became known.18 Petitioner Dr. Harry Ostrer ("Ostrer"), a researcher at New
York University, often sent his patients' DNA samples to GDL for testing.19
When Myriad learned of this, it sent letters to GDL and Ostrer, informing
them of its patents and alleging that the genetic testing was an infringement
of those patents.20 The letters offered collaboration licenses that permitted
very limited BRAC related testing. GDL responded by agreeing to cease
such testing and informed Ostrer of its decision.21 Myriad continued to assert
its patent rights against others by filing infringement suits that led to settle-
ments whereby defendants agreed to stop conducting BRCA testing.22
III. DESCRIPTION OF PLAINTIFFS' CLAIM
The Association of Molecular Pathology, along with certain medical pa-
tients, advocacy groups, and doctors, initially filed the suit in the District
Court of the Southern District of New York, seeking declaratory relief on the
grounds that Myriad's patents did not cover patentable subject matter consis-
tent with the Patent Act, and were thereby invalid23 Plaintiffs argued: (1)
DNA sequences occur naturally and are therefore exempt from patent protec-
tion; (2) Myriad neither created nor altered the naturally occurring genetic
information of the genes, or the genetic structure of the DNA.24 The patents-
14. Id.
15. Id.
16. Myriad Genetics, 133 S. Ct. at 2113.




21. Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d
1303, 1315 (Fed. Cir. 2012) cert. granted in part, 133 S. Ct. 694 (2012) and
aff'd in part, rev'd in part sub nom. Myriad Genetics, 133 S. Ct. at 2120
(2013).
22. Id.
23. Id. at 1309.
24. Id. at 1326.
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in-suit included isolated DNA containing all or part of the BRCAI and
BRCA2, and methods used to assess the gene sequences to identify genetic
mutations associated with cancer risks.25
IV. PROCEDURAL AND SUBSTANTIVE HISTORY
The District Court of the Southern District of New York held that Myr-
iad's patents for isolated DNA sequences, as well as the methods used to
conduct the genetic testing, were both invalid because neither the methods
nor the isolation of DNA changed the composition of the naturally-existing
products in a manner that made the isolated DNA "markedly different."26
On July 29, 2010, the United States Court of Appeals for the Federal
Circuit affirmed in part and reversed in part, holding that the DNA sequences
were patentable because by isolating the sequences, Myriad changed the mo-
lecular composition of what existed naturally.27 Similarly, the Federal Circuit
held that the method claim of screening cancer patients via changes in cell
growth rates was a patentable method, even though it involved a basic scien-
tific principle, because the method involved an additional transformative
step.28 Finally, the court held that the method claim involving comparing and
analyzing BRCA sequences was not patentable because it involved only ab-
stract mental processes. 29
On March 26, 2012, the United States Supreme Court granted a petition
for writ of certiorari and vacated the judgment in light of the decision in
Mayo Collaborated Services v. Prometheus Laboratory, Inc.30 However, on
remand August 16, 2012, the Federal Circuit again came to its prior
conclusion.31
On November 30, 2012, the United States Supreme Court again granted
the petition for writ of certiorari,32 and a decision was made on June 13,
2013.33
V. SUPREME COURT HOLDING AND OVERVIEW OF RATIONALE
The Court unanimously held: (1) A naturally occurring DNA segment
was a product of nature and not entitled to patent eligibility merely because it
25. Id. at 1309-10.
26. See id. at 1330.
27. Ass'n for Molecular Pathology, 689 F.3d at 1331.
28. Id. at 1336.
29. Id. at 1334.
30. Id. at 1308.
31. Id. at 1309.
32. Myriad Genetics, 133 S. Ct. at 2116.
33. Id. at 2120.
[Vol. XVH
Laws of Nature Versus Man Made Creations
was isolated;34 and (2) cDNA was synthetically created in a laboratory and
was patent eligible because formulating it included the additional step of re-
moving certain unwanted naturally-occurring codes, as is required in order to
sever and isolate.35 The rationale was that the isolated DNA sequence of
BRCA1 and BRCA2 genes exist in that same genetic location and order in
the human body with or without the isolation.36 Although isolating the seg-
ment was a groundbreaking discovery, the usefulness of the discovery was
not a factor in determining patent eligibility.37 In order to claim patent rights,
Myriad needed to have conducted at least one additional step to ensure that
the product it claimed to have created was an act of invention rather than a
mere discovery.38
VI. COURT'S RATIONALE
The Court began its analysis by reiterating its long-standing decision
that the Patent Act implicitly excludes laws of nature, natural phenomena,
and abstract ideas from patent eligibility; such subject matters are basic tools
of scientific and technological work.39 The exception was created to ensure
that broad grants of patents covering such basic tools would not inhibit inno-
vation, thereby directly conflicting with the very purpose of patent law.40
Products of nature, in that case, should be equally available to everyone.4 '
The Court relied on its previous decision in Diamond v. Chakrabarty, which
held that a product of nature is only patentable if its characteristics are mark-
edly different from what is found in nature.42
Myriad contended that the isolated DNA was not a product of nature
because the extensive process of isolation rendered the segment different
from the non-isolated segment found in nature.43 Myriad's argument rested
on the presumption that all compositions of matter were ultimately derived
from nature, therefore a rule requiring a distinct composition from what natu-
rally existed would make patents impossible to obtain.44
In response, petitioners argued that products of nature were exempt
from patent protection, regardless of whether the product had been changed
34. Id. at 2117.
35. Id. at 2119.
36. Id. at 2116.
37. Id. at 2117.
38. Myriad Genetics, 133 S. Ct. at 2117.
39. Id. at 2116 (quoting Mayo, 132 S. Ct. at 1293).
40. Chakrabarty, 447 U.S. at 309.
41. Id.
42. See id.
43. Ass'n for Molecular Pathology, 689 F.3d at 1325.
44. Id.
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from its natural form, unless the change is one that alters the product's name,
character, or use thereby making it markedly distinct from its natural charac-
ter.45 This argument relies on the presumption that isolation did not alter the
genetic composition of the DNA segment enough to justify completely ban-
ning anyone's use of that genetic composition.46
The United States Patent and Trademark Office ("PTO") took the posi-
tion that man-made DNA molecules (such as cDNA) created by removing
certain codes are patent eligible; whereas mere isolations of DNA segments,
without anything more, are not.47
The Court ultimately deferred to its precedent: no matter how incredible
and advantageous a discovery, that particular fact alone does not satisfy the
Patent Act requirement.48 Myriad's discovery of the gene sequence location
was groundbreaking information in the field of medical science.49 However,
the patents obtained in light of this discovery simply described the exten-
sively repetitive process of narrowing down possible locations of the genes,
not the creation of a new process.5o The information that BRCA genes could
be used to assess cancer risk was known before Myriad discovered the loca-
tion.51 The Court acknowledged that the process of discovering the location
required comprehensive effort; but effort, like usefulness, was not sufficient
to satisfy the Patent Act.52
The Court held that even though isolating the genes involved breaking
chemical bonds, the claims that Myriad patented did not rely on the chemical
changes caused by breaking the bonds.53 Myriad's claims involved the infor-
mation found in the BRCAI and BRCA2 genes. 54 Had Myriad only patented
the unique segment of the two genes that it had isolated, others could still
have used the information in the genes by breaking the chemical bonds in a
way that resulted in DNA sequences including only BRCAI gene or BRCA2
gene, or both genes with other additional genes.55 Such isolations would
again give others the information found in those genes.5 6 Therefore, ob-
taining a patent to keep others from isolating genes in the particular sequence
45. Id. at 1326; see Hartranft v. Wiegmann, 121 U.S. 609, 615 (1887).
46. Ass'n for Molecular Pathology, 689 F.3d at 1326.
47. Id. at 1349-50.
48. See Myriad Genetics, 133 S. Ct. at 2117; see also 35 U.S.C § 101.
49. Myriad Genetics, 133 S. Ct. at 2117.
50. Id. at 2118.
51. Id. at 2110.
52. Id.
53. Id.
54. Id. at 2118.
55. Myriad Genetics, 133 S. Ct. at 2118.
56. Id.
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of the molecule it discovered would not award Myriad a monopoly in the
BRCA genetic information.57 Thus, even though the Court upheld the patent-
ability of the actual cDNA molecule pieced together by Myriad, the genetic
information found in that molecule was not patentable.58
The Court also rejected Myriad's argument that the PTO's past practice
of patenting genes should be given deference.59 The Court came to this con-
clusion by distinguishing the past patentable plant genes from the genetic
information in dispute.60 The plant genes were patentable under the Patent
Act due to certain other statutes that provided such patent protection to cer-
tain plant breeds.61 Congress subsequently endorsed the special protection in
an amendment of the Patent Act.62 There had been no such Congressional
endorsement in the context of human genes. 63
The Court expressly stated that its holding did not apply to any method
claims. 64 If Myriad discovered the location of BRCAI and BRCA2 genes by
isolating the genes via a method that it had invented, it potentially could have
obtained a method patent.65 But since the method Myriad employed to isolate
the DNA was a widely used scientific method, and any scientists searching
for the location would have likely used the same method, that method is not
an invention for purposes of patent protection.66
VII. CRITIQUE OF COURT'S APPROACH
The human body is full of valuable undiscovered knowledge that could
lead to significant medical advancement. Discovery of such knowledge often
involves comprehensive understanding of biological complexities and ex-
haustive medical research. Long hours of labor are typically common in un-
covering useful information. However, such hard work and labor may no
longer be enough to successfully claim a right in the discovery of that con-
structive knowledge. Although no discovery could arguably be more useful
than one that could potentially save lives, these discoveries are often re-
warded with fewer rights than trivial discoveries that require an additional
57. See id.
58. Id. at 2119.
59. Id. at 2118-19 (citing J.E.M. Ag Supply, Inc., v. Pioneer Hi-Bred Int'l, Inc.,
534 U.S. 124 (2008)).
60. Id.
61. Myriad Genetics, 133 S. Ct. at 2118 (citing 7 U.S.C. § 2321 and 35 U.S.C.
§§ 161-64).
62. Id.
63. Id. at 2118-19.
64. Id.
65. Id.
66. Id. at 2119-20.
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step to be of any use. This is because usefulness and effort are no longer
relevant in determining whether a discovery is worthy of patent protection.
The Myriad Court was faced with the inevitable dilemma of what level
of protection will adequately encourage useful innovation, and at the same
time, promote additional inventions based on pre-developed concepts and
tools.67 These conflicting goals would not be possible without a sufficient
balance. If the Court were too cautious in approving patents for experimental
processes conducted on naturally-occurring products, it would remove the
financial incentive to conduct groundbreaking scientific experiments. On the
other hand, being too generous in awarding patent protection to such experi-
mentation could hinder other potential discoveries of equal importance by
keeping others from utilizing the fruits of valuable research and
experimentation.
In the case of medical science, particularly where human genes with the
potential to save live are involved, the Court has another consideration to
keep in mind: When will awarding a monopoly in essential scientific tools
and information place too high of a burden on those who have the propensity
to benefit most from such valuable innovations? In this case, granting human
genome patents would not only hinder scientific innovation, it would also
keep patients from easy and cost-effective access to the medical advance-
ment achieved from the study of such genes, thereby detrimentally affecting
health care.
After undergoing the foregoing considerations, the Court ultimately fol-
lowed precedent, and continued to uphold its rationale that certain natural
laws and phenomena are exempt from the Patent Act.68 The Court seemingly
asserts that providing economic incentives by broadly privatizing science and
technology do not necessarily have the desired consequences that the law
seeks to accomplish.69
In Chakrabarty, a microbiologist filed patent claims for certain naturally
existing bacterium, which had the propensity to break down multiple compo-
nents of crude oil.70 The Supreme Court held that not all living things were
exempted from the Patent Act. 71 Instead it found that the bacterium at issue
constituted a newly manufactured microorganism because its characteristics
markedly differed from the characteristics of bacterium found in nature. 72
The bacterium in Chakrabarty, unlike the human genes in Myriad, did un-
dergo an additional process that sufficiently altered its composition.73 The
67. See Myriad Genetics, 133 S. Ct. at 2116.
68. Id.
69. See id.
70. Chakrabarty, 447 U.S. at 305.
71. Id. at 311.
72. Id. at 310.
73. Id. at 305.
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newly manufactured bacterium was a product of human ingenuity "having a
distinctive name, character, and use." 74 No naturally occurring bacteria had
all the characteristics necessary to break down multitude components of
crude oil, unlike the BRCA gene segment that was naturally capable of as-
sessing cancer risks.75
In Mayo, the patent claims at issue included specific dosage of drugs
that were metabolized differently by patients with autoimmune diseases.76
The Supreme Court found the patents invalid because the concept of the cor-
relation between concentrations of metabolites in blood and ineffective dos-
ages of thiopurine drugs was common knowledge,77 just as the Court found
in Myriad that the concept that mutations in BRCA genes could help deter-
mine propensity to cancer was widely known. Like the defendant in Myriad
whose experiments comprised of repetitive tests to ascertain the precise loca-
tion of naturally existing genes, the defendant in Mayo merely conducted
extensive experiments to determine the correct dosages of a pre-existing
drug.78
The Supreme Court in Funk Brothers Seed Co. v. Kalo Inoculant Co.
found that patentee had discovered only "some of the handiwork of nature."79
In this case, it was widely known that bacteria could fix nitrogen, and farm-
ers routinely "inoculated" their crops with bacteria to manipulate nitrogen
levels in the soil to improve it.80 However, the same bacteria could not be
used to achieve the optimum nitrogen levels in all plants.81 The patentee
combined several different bacteria to formulate a single inoculant and ob-
tained a patent.82 The Court again held that the combination of bacteria did
not alter the bacteria that existed naturally in any way, therefore making the
mixture of bacteria ineligible for patent protection.83 Permitting a patent for
merely mixing the naturally occurring bacteria, similar to the mere finding of
the BRCA location in Myriad, would be equivalent to allowing Newton ex-
clusive rights to the laws of gravity. 84
74. Id. at 309-10 (quoting Hartranft, 121 U.S. at 615).
75. See id. at 305.
76. Mayo, 132 S. Ct. at 1290.
77. Id. at 1291.
78. Id. at 1290-91.
79. Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 131 (1948).
80. Id. at 128-29.
81. Id.
82. Id. at 130.
83. See id. at 132; see also Mayo, 132 S. Ct. at 1293 ("A new mineral discovered in
the earth or a new plant found in the wild is not patentable subject matter."
Thus, Newton could not have patented the law of gravity.).
84. See Funk Bros. Seed, 333 U.S. at 130.
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The Myriad Court followed precedence and uniformly applied the law
to the facts of the case. 85 The holding, therefore, does not deviate from the
already existing law regarding patent eligibility in general, other than provid-
ing further clarification of the meaning of "natural law" in connection with
human genome sequences. 86 So even though the decision may not be ground-
breaking in the context of exceptions to patent law, the Court once again held
that when it comes to choosing between encouraging advantageous natural
discoveries and preserving natural tools, the preference will be always be
given to the latter without evidence of some concrete creation.87 After all,
like the Court stated in Mayo, neither Einstein, nor Newton could have pat-
ented their discovery of natural laws: E=mc 2 and gravity.88 Had such patents
been permitted, any advancement in physics and technology since then
would have ceased to exist. Privatizing valuable scientific tools discourages
growth in the fields related to the patent. For example a researcher who
wants to find a cure for breast cancer would first have undergo extensive
negotiations with all the various patent holders who have pecuniary claims to
any of the information relevant to the mutations of the gene. There is little
doubt that such a time consuming and financially burdensome procedure may
effectively influence the researcher in extending his efforts elsewhere. There-
fore, in its decision to limit patent law to truly innovative discoveries, the
Myriad Court reached a sound conclusion supported by judicial precedence.89
When a discovery involves a natural phenomenon, it must be accompanied
with an additional useful invention to achieve patentable status.90
VIII. CONCLUSION
Before the Supreme Court followed suit, various other parts of the
world had taken a narrow approach towards patent eligibility,91 thereby, ena-
bling researchers to advance more quickly than American researchers. For
instance, a French physicist found one mutation by using the BRCA DNA
sequence before Myriad's patent was held invalid,92 exemplifying that per-
mitting restrictive use of naturally-occurring products keeps others from us-
ing the information contained in the products to come up with new and
unique scientific principles.
While the Myriad Court merely reiterated what it already previously
established: Patent protection will only be rewarded for human ingenuity and
85. See Myriad Genetics, 133 S. Ct. at 2109-10.
86. See id.
87. Id. at 2109.
88. Mayo, 132 S. Ct. at 1293.
89. See Myriad Genetics, 133 S. Ct. at 2109-10.
90. Id. at 2109.
91. See Andrews, supra note 9, at 86.
92. Id. at 90.
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true innovations, the decision greatly impacts geneticists, health care profes-
sionals, and patients. No longer may a person economically benefit from an
existing scientific principle by simply discovering the natural components of
that principle. To analogize, an amateur cook cannot take a widely known
recipe, mix up the necessary ingredients, and claim that no one else, not even
the chef who originally came up with the recipe, can ever use that recipe or
any other recipes that include those pre-existing ingredients because discov-
ering all the ingredients was a tedious task. The law in Myriad is clear: mere
discoveries of pre-existing natural products, no matter how difficult and cum-
bersome, are not "innovations" in the context of the Patent Act.

